Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab, Famitinib Malate, and Chemotherapy in Recurrent/Metastatic Cervical Cancer
NCT07627620Phase 2Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Jun 2026
- Primary completion
- Sep 2027
01
Overview
A Phase 2 trial of camrelizumab, famitinib in Cervical Cancer (CC), sponsored by Hunan Cancer Hospital. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
camrelizumabfamitinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07627620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07627620.